Expression of multidrug resistance-associated protein (MRP) in human gliomas.
about
Progress and perspectives on targeting nanoparticles for brain drug delivery.Nanomedicine therapeutic approaches to overcome cancer drug resistanceBlock copolymer micelles with acid-labile ortho ester side-chains: Synthesis, characterization, and enhanced drug delivery to human glioma cells.Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.Association between DNA methylation and multidrug resistance in human glioma SHG-44 cellsInhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.Pharmacotherapy for adults with tumors of the central nervous system.Targeted delivery of nano-therapeutics for major disorders of the central nervous system.Cancer-targeting siRNA delivery from porous silicon nanoparticles.Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells.The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects.Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects.Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma.Differences in the expression pattern of P-glycoprotein and MRP1 in low-grade and high-grade gliomas.
P2860
Q26740580-AFC6A381-ABC3-4C2A-80E6-6CB49F27FD36Q27011692-3CE35251-064E-48F4-A447-A4C66552A2F1Q33782767-FE525669-9B54-4F70-B5A8-DE53797BB100Q34204238-1C31F872-F238-456F-8D9C-59981B0609C0Q34540841-2A85EF1C-53ED-44D1-AB21-B82C5921C631Q34743441-E716FBBE-30CB-455F-94D3-9D2BEB4A3298Q37308322-C8A608BD-7804-4EDC-B118-EBED868E3878Q37353276-8A3DF7CD-6DBD-4822-A1D4-34B70FC8B7D1Q38116765-ECF302C2-2FF2-4190-A531-FDE9C85559FCQ39018787-AC3DBED2-24D2-42A9-9233-A80B07A69046Q39083216-817B5F02-320A-4768-BCD6-3CA529D91CC8Q39294543-38C501DA-A16A-4A06-96CD-39C7EE685632Q39313430-61406AC0-4CB4-4319-BE8E-28559C42603CQ39836322-0E74E168-E73F-4105-8130-49D119B40CE7Q50253921-62AB4DCB-A34F-4B6C-9CFF-7CC3AA6DEAEAQ52719561-64D10598-D732-40A5-A4A5-CD9AEA36FAD8Q55465808-289F8295-D3A2-48C2-9A75-0A436FDB7FF5
P2860
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
@ast
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
@en
type
label
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
@ast
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
@en
prefLabel
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
@ast
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
@en
P2093
P356
P1476
Expression of multidrug resistance-associated protein (MRP) in human gliomas.
@en
P2093
P2888
P304
P356
10.1023/A:1026528926482
P577
2000-09-01T00:00:00Z
P6179
1013797347